Published in J Med Virol on January 01, 1984
Herpes simplex virus glycoproteins E and I facilitate cell-to-cell spread in vivo and across junctions of cultured cells. J Virol (1994) 3.39
Glycoproteins E and I facilitate neuron-to-neuron spread of herpes simplex virus. J Virol (1995) 2.52
A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G. J Virol (1989) 2.08
Identification and expression of human cytomegalovirus transcription units coding for two distinct Fcgamma receptor homologs. J Virol (2002) 1.92
Herpes simplex virus type 1 Fc receptor protects infected cells from antibody-dependent cellular cytotoxicity. J Virol (1991) 1.73
In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor. J Virol (1998) 1.59
Virus attenuation after deletion of the cytomegalovirus Fc receptor gene is not due to antibody control. J Virol (1998) 1.44
Herpes simplex virus type 1 encodes two Fc receptors which have different binding characteristics for monomeric immunoglobulin G (IgG) and IgG complexes. J Virol (1990) 1.38
Characterization of domains of herpes simplex virus type 1 glycoprotein E involved in Fc binding activity for immunoglobulin G aggregates. J Virol (1994) 1.36
Identification and expression of a murine cytomegalovirus early gene coding for an Fc receptor. J Virol (1994) 1.24
Feeling manipulated: cytomegalovirus immune manipulation. Virol J (2009) 1.19
Direct evidence for antibody bipolar bridging on herpes simplex virus-infected cells. Immunology (1992) 0.93
Immune responses to herpesviral vectors. Hum Gene Ther (2009) 0.76
Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res (1995) 1.68
Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. Urology (2000) 1.53
Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer (1997) 1.29
Viral and epidemiologic studies of idiopathic sudden hearing loss. Otolaryngol Head Neck Surg (1983) 1.14
A deficit of chondroitin sulfate proteoglycans on the bladder uroepithelium in interstitial cystitis. Urology (1996) 1.13
Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol (1996) 1.11
Immunoglobulin changes in a pediatric otolaryngic patient sample subsequent to T & A. J Laryngol Otol (1972) 1.07
Recurrent adenotonsillitis: a new concept. Laryngoscope (1976) 1.06
Cloning and characterization of UROC28, a novel gene overexpressed in prostate, breast, and bladder cancers. Cancer Res (2000) 1.04
Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol (2000) 1.02
Secretory otitis media. An immune complex disease. Ann Otol Rhinol Laryngol (1976) 1.02
Isolation and identification of human lung tumor-associated antigens. Cancer Res (1977) 1.02
Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States. Urology (1998) 0.97
An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. J Urol (1996) 0.96
Serous otitis media. Immunoglobulin and lysozyme levels in middle ear fluids and serum. Ann Otol Rhinol Laryngol (1973) 0.95
Immune complexes, serum proteins, cell-mediated immunity, and immune regulation in patients with squamous cell carcinoma of the head and neck. Cancer (1986) 0.93
Lymphomatoid granulomatosis and Epstein-Barr virus. Cancer (1982) 0.93
Update on the appropriate staging evaluation for newly diagnosed prostate cancer. J Urol (1997) 0.92
Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. Urology (1999) 0.90
Human prostate-specific transglutaminase gene: promoter cloning, tissue-specific expression, and down-regulation in metastatic prostate cancer. Urology (1999) 0.89
Abscesses of the head and neck. Laryngoscope (1974) 0.88
Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. J Urol (1995) 0.87
Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF. Prostate (2004) 0.86
Abrogation of cell-mediated immunity by a serum blocking factor isolated from patients with infectious mononucleosis. J Infect Dis (1979) 0.85
The tonsil and adenoid dilemma: medical or surgical treatment? Otolaryngol Clin North Am (1974) 0.85
Epstein-Barr virus, fatal infectious mononucleosis, and Hodgkin's disease in siblings. Cancer (1983) 0.84
An antiviral substance in the tissues of mice acutely infected with lymphocytic choriomeningitis virus. J Gen Virol (1971) 0.84
Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics. Urology (2001) 0.84
Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder. J Urol (1998) 0.83
A human tumour-associated membrane antigen from squamous-cell carcinoma of the lung. Br J Cancer (1980) 0.83
In vitro IgM antibody synthesis by human tonsil-derived lymphocytes. J Immunol (1973) 0.83
Long-term primary culture of epithelial cells from rainbow trout Oncorhynchus mykiss) liver. In Vitro Cell Dev Biol Anim (1995) 0.83
Phenylbutyrate-induced apoptosis and differential expression of Bcl-2, Bax, p53 and Fas in human prostate cancer cell lines. Anal Quant Cytol Histol (2000) 0.82
Protein-A antibody-binding TPAAB) technique for detection of tumor-associated membrane antigen (TAMA) of Lewis lung carcinoma. Int J Cancer (1980) 0.82
Transrectal ultrasound-guided biopsy causes hematogenous dissemination of prostate cells as determined by RT-PCR. Urology (1997) 0.82
Chronic serous otitis media: an immune complex disease. Trans Sect Otolaryngol Am Acad Ophthalmol Otolaryngol (1977) 0.81
The implication of viruses in idiopathic sudden hearing loss: primary infection or reactivation of latent viruses? Otolaryngol Head Neck Surg (1981) 0.81
Pathophysiology of serous otitis media. Am J Otol (1986) 0.80
Immune monitoring protocol for patients with carcinoma of the head and neck. Preliminary report. Ann Otol Rhinol Laryngol (1979) 0.80
The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. J Cell Biochem Suppl (1994) 0.80
The tonsils and adenoids. Clin Otolaryngol Allied Sci (1977) 0.80
Lymphoproliferative changes induced by infection with a lymphotropic herpesvirus of guinea pigs. J Infect Dis (1984) 0.79
Clinical sensitivity of p53 mutation detection in matched bladder tumor, bladder wash, and voided urine specimens. Cancer (2001) 0.78
Immunologic identification of Epstein-Barr virus early antigen in a P3HR-1 cell extract. J Natl Cancer Inst (1976) 0.78
Circulating IgA immune complexes in head and neck cancer, nasopharyngeal carcinoma, lung cancer, and colon cancer. Cancer (1987) 0.78
Development of secondary structure, growth characteristics and cytogenetic analysis of human transitional cell carcinoma xenografts in scid/scid mice. J Urol (1996) 0.78
Immunoglobulin allotypes in patients with squamous cell carcinoma of the head and neck. Cancer (1982) 0.78
Value of computer-assisted quantitative nuclear grading in differentiation of normal urothelial cells from low and high grade transitional cell carcinoma. Anal Quant Cytol Histol (1998) 0.77
Epstein-Barr nuclear antigen (EBNA) carrying lymphocytes in human palatine tonsils. J Gen Virol (1976) 0.77
Biologic and molecular characterization of the IgG serum blocking factor (SBF-IgG) isolated from sera of patients with EBV-induced infectious mononucleosis. J Immunol (1981) 0.77
Comparative analysis of DNA content in polyomavirus-infected urothelial cells, urothelial dysplasia and high grade transitional cell carcinoma. Anal Quant Cytol Histol (1997) 0.77
Artificial neural networks in urology: Update 2000. Prostate Cancer Prostatic Dis (1999) 0.77
Serum ferritin as a tumor marker in patients with squamous cell carcinoma of the head and neck. Cancer (1986) 0.77
A new class of synthetic biological response modifiers: the methylfurylbutyrolactones (Nafocare B). J Biol Response Mod (1986) 0.77
Osteogenesis imperfecta tarda in a child with hyper-IgE syndrome. Am J Dis Child (1982) 0.76
Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia. Urology (1996) 0.76
From methylglyoxal to new immunopotentiating ascorbic acid derivatives. Acta Biochim Biophys Hung (1987) 0.76
Association of Epstein-Barr virus with acute exudative tonsillitis. Otolaryngol Head Neck Surg (1982) 0.75
Sensitive, nonradioactive differential display method using chemiluminescent detection. Biotechniques (1996) 0.75
Deoxyribonucleic acid ploidy enhances the cytological prediction of recurrent transitional cell carcinoma of the bladder. J Urol (1997) 0.75
EBV antigens in lymphocytes of patients with exudative tonsillitis, infectious mononucleosis and Hodgkin's disease. Int J Cancer (1978) 0.75
Epstein-Barr virus associated with episodes of recurrent tonsillitis. Arch Otolaryngol (1975) 0.75
Separation of the complement-fixing and early antigens from Epstein-Barr soluble antigen. J Natl Cancer Inst (1977) 0.75
Microbiology of the middle ear and nasopharynx. Ann Otol Rhinol Laryngol (1971) 0.75
Detection of Epstein-Barr virus-coded antigens in lymphocytes isolated from defined patient samples. IARC Sci Publ (1978) 0.75
Ecological alterations of oral microflora subsequent to tonsillectomy and adenoidectomy. J Laryngol Otol (1972) 0.75
Soluble immune complexes in sera from head and neck cancer patients: a preliminary report. Otolaryngology (1979) 0.75
Neural net-based identification of cells expressing the p300 tumor-related antigen using fluorescence image analysis. Cytometry (1997) 0.75
Soluble tumor-associated markers in lung cancer extracts. Oncology (1981) 0.75
Epstein-Barr virus infection and neoplasia. Otolaryngol Head Neck Surg (1981) 0.75
Antibody response to a solubilized tumor-associated membrane antigen (TAMA) from the murine Lewis lung tumor. Cancer Immunol Immunother (1983) 0.75
Clinical significance of viral latency. Laryngoscope (1976) 0.75
Quantitative alterations in the ecology of the oropharyngeal microflora subsequent to tonsillectomy and adenoidectomy. Trans Am Acad Ophthalmol Otolaryngol (1974) 0.75
Stimulation of human PMNs in vitro by a succinimide molecular complex of methylfurylbutyrolactone. J Biol Response Mod (1986) 0.75
Epstein-Barr virus genome carrying lymphocyte subpopulations of human palatine tonsils. Proc Soc Exp Biol Med (1977) 0.75
Early antigen titers in pediatric patients with acute cervical lymphadenitis. Otolaryngol Head Neck Surg (1982) 0.75